No abstract

Community-acquired pneumonia (CAP), particularly in patients infected with multidrug resistance (MDR) Gram-negative bacilli, is a common and potential serious associated illness leading to considerable morbidity and mortality. Pseudomonas aeruginosa is the second most common pneumonia-causing pathogen, followed by K. pneumonia and S. aureus in India. This resistance is one of the most barriers to bacterial eradication and clinical cure of Pseudomonas infection. This delay in the management of MDR Pseudomonas aeruginosa with antibiotics can lead to increased mortality and morbidity. Here we discuss a case of a CAP caused by pathogen Pseudomonas aeruginosa which was resistant to the first line of antibiotics, piperacillin-tazobactam & cefoperazone sulbactam but sensitive to Supime (cefepime + sulbactam). Supime 3gm BD with 30 minutes of infusions for 7 days was effective in treating and discharging the patient from the hospital. Supime was safe and efficacious to treat hospitalized CAP patient infected with MDR Pseudomonas aeruginosa.

Diabetic patients are at significant risk of developing neuropathy, leading to a diabetic foot injury. Complications of diabetic foot injury may lead to gangrene and non-traumatic lower extremity amputations. Diabetic patients with diabetic foot ulcers are more prone to bacterial infections and are associated with high chances of amputation. The diabetic patient flora provides an ideal environment for Gram-positive and Gram-negative bacterial growth, leading to increased morbidity and mortality. The antimicrobial-resistant Gram-negative bacterial infections in diabetic patients have a higher probability of amputation. Here we discuss a case of a 70-year male diabetic patient successfully treated with Supime (cefepime plus sulbactam) who had undergone an amputation of the right great toe and infected left foot ulcer due to ESBL producing K. Pneumonia.

Borkar et al. Use of an autologous platelet -rich concentrate in hypospadias repair : a systematic review and meta-analysis. Inplasy protocol 202290098.